Skip to main content
Clinical Trials/CTRI/2023/10/058414
CTRI/2023/10/058414
Recruiting
N/A

Evaluation of effect of genetic polymorphism on antidiabetic medication in Indian patients with Type 2 Diabetes for development of a pharmacogenomic test for T2DM patients - NI

Chellaram Diabetes Research Centre0 sites0 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Sponsor
Chellaram Diabetes Research Centre
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational

Investigators

Sponsor
Chellaram Diabetes Research Centre

Eligibility Criteria

Inclusion Criteria

  • Subjects from Indian population diagnosed with Type 2 diabetes according to the criteria of the American Diabetes Association.
  • Subjects having with HbA1c in the range of 7\.5–12% and either on monotherapy or combination therapy on antidiabetic drugs.
  • Subjects over 18 years old and below 60 years
  • Subjects who agree with the written informed consent to participate in the study

Exclusion Criteria

  • Other than Indian ethnicity
  • Under 18 years old
  • Pregnant or lactating women
  • Patients with malignancies, and chronic kidney disease stage 3–5, liver cirrhosis
  • Presently suffering from congestive heart failure requiring pharmacologic treatment (medical history)
  • Past history of urinary or gastric retention or narrow\-angle glaucoma
  • Presently severe anaemia
  • Taking a medication that could confound study results, such as known substrates or inhibitors of OCT3 and MATE1, such as cimetidine.
  • They do not provide consent to participate in the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials